DENTSPLY SIRONA Maps 24-Month Turnaround After Soft 2025

DENTSPLY SIRONA ((XRAY)) has held its Q4 earnings call. Read on for the main highlights of the call.

DENTSPLY SIRONA’s latest earnings call struck a cautiously optimistic tone as management balanced a soft 2025 revenue performance with clear signs of margin discipline and cash generation. Executives acknowledged volume weakness, tariffs and impairments, but emphasized a detailed 24‑month Return to Growth plan and a sharper capital allocation strategy aimed at restoring growth and shareholder value over time.

Q4 Revenue Momentum Masks Underlying Topline Pressure

Q4 2025 revenue reached $961 million, with reported sales up 6.2% and constant‑currency growth of 2.5%, helped by one‑time Byte refunds and distributor pre‑buys plus FX benefits. Management cautioned that these tailwinds will fade but expressed confidence in achieving positive sequential sales momentum in the second half of 2026.

EBITDA Margin Expansion Highlights Cost Discipline

For full‑year 2025, adjusted EBITDA margin expanded 150 basis points to 18.1%, driven mainly by lower SG&A and tighter cost control despite pressure on gross profit. This improvement signals management’s ability to protect profitability even as revenue declines and provides a base to fund reinvestment in growth initiatives.

Solid Profitability and Cash Flow Support Strategic Flexibility

Q4 adjusted EPS rose to $0.27, up 4.9% year over year, while full‑year adjusted EPS of $1.60 came in on guidance. Operating cash flow reached $235 million and free cash flow $104 million in 2025, leaving the company with $326 million in cash and net debt at 3.0 times EBITDA, enough to pursue balance sheet strengthening and selective buybacks.

Pockets of Strength Across Products and Regions

Several areas performed well despite the broader slowdown, with EDS constant‑currency sales up 4% in Q4 and preventative products jumping 17%. OIS constant‑currency sales rose 6.9%, Wellspect grew 1.9% with a strong 15% gain in the U.S., and imaging delivered high single‑digit to double‑digit growth across Europe and the rest of the world.

Return‑to‑Growth Plan Centers on Investment and Efficiency

Management laid out a five‑pillar, 24‑month Return to Growth plan that will boost R&D by double digits and lift clinical education spending by 50%. The company will reorganize commercial teams, scale manufacturing and distribution, and target roughly $120 million in annual run‑rate savings, with much of the benefit earmarked to fund these growth investments.

Capital Allocation Shift Favors Deleveraging and Buybacks

DENTSPLY SIRONA eliminated its roughly $128 million annual dividend, redirecting cash toward debt reduction and disciplined share repurchases. Management framed this as a move to strengthen the balance sheet, move toward investment‑grade metrics and create more flexible, total‑return‑oriented shareholder value rather than income‑focused payouts.

Full‑Year Revenue Decline Highlights Structural Headwinds

Full‑year 2025 sales fell to $3.68 billion, down 3% on a reported basis and 4.3% in constant currency, with pressure most acute in CAD/CAM and implants across regions. CTS constant‑currency sales declined 1.9% in Q4, while implant segment revenues fell by high single digits, underscoring ongoing demand and competitive challenges.

Noncash Impairment Underscores Tariff and Volume Challenges

The company recorded a $144 million noncash, net‑of‑tax impairment charge in Q4 tied to goodwill and intangibles in CTS and OIS, reflecting tariff impacts, volume declines and competitive pressures. While the charge does not affect cash, it highlights a tougher operating environment in key businesses and the urgency of the turnaround plan.

Tariffs Weigh on Gross Profit and Margins

Adjusted EBITDA margin in Q4 slipped 10 basis points to 14.1% as gross profit contracted by 300 basis points on lower volumes, adverse mix and tariffs. Tariffs alone reduced gross profit by about $15 million in Q4 and roughly $23 million for the full year, a meaningful headwind that management must offset through pricing, sourcing and efficiency.

Byte and Dealer Inventory Dynamics Distort Comparisons

Byte‑related items cut about 1.9% from full‑year constant‑currency growth, while last year’s Byte refunds and distributor pre‑buys created a Q4 tailwind. Looking ahead, the shift to a drop‑ship model is expected to create roughly a $30 million dealer inventory sell‑through headwind in the first half of 2026, complicating near‑term sales visibility.

Ortho and SureSmile Still Searching for Traction

SureSmile declined low single digits in Q4 overall, with U.S. volumes down around 10% even as Europe grew 15%, underscoring mixed geographic performance. Management described orthodontics and software modernization as longer‑term initiatives that are unlikely to deliver material revenue contributions in the near term.

Earnings and Free Cash Flow Under Pressure in 2025

Despite margin improvements, full‑year adjusted EPS slipped by $0.07 to $1.60, partly due to a higher tax rate, and free cash flow remained modest at $104 million. That limited the company’s near‑term excess cash, increasing the importance of the dividend cut and cost savings plan to fund strategic investments and balance sheet repair.

Restructuring Costs and Execution Risks Loom

The restructuring program designed to unlock about $120 million in annual savings will require $55 million to $65 million in nonrecurring charges through 2027, most of it cash. Management stressed that successful execution of the Return to Growth plan is critical, acknowledging timing and implementation risks that investors will monitor closely.

Leverage and Investor Perception of the Balance Sheet

With net debt at 3.0 times EBITDA, leverage sits above the comfort zone for some investors, prompting management to prioritize debt paydown. While the dividend elimination may disappoint income‑oriented shareholders, the company argues that deleveraging and targeted buybacks should ultimately support a healthier valuation and reduced financial risk.

Guidance Signals Investment‑Heavy 2026 With Modest Declines

For 2026, management guided net sales to $3.5 billion to $3.6 billion, implying operational growth of –3% to –1% and excluding both a Byte headwind and dealer sell‑through impact, with sequential improvement expected in the second half and a targeted U.S. turnaround by Q4. Adjusted EPS is forecast at $1.40 to $1.50 as the company ramps R&D, commercial and Wellspect investments, funds restructuring to unlock about $120 million in savings and channels cash from the eliminated dividend toward debt reduction and measured buybacks.

The call painted a picture of a company in transition, trading near‑term growth and income for reinvestment, efficiency and balance sheet repair. While revenue headwinds, tariffs and execution risk remain real, DENTSPLY SIRONA’s clear cost actions, targeted investments and capital allocation reset provide a structured path that could reward investors if management delivers on its 24‑month Return to Growth roadmap.